2022 VIDA Highlights

As we look forward to all that the new year has in store, we've also taken a moment to look back on a productive 2022.

We hope this holiday season finds you healthy and joyful. The end of the year provides an opportunity to reflect on the last 12 months, as well as look forward to 2023.

Milestones and Announcements

In April, we received market authorization in Japan for our VIDA Insights® software, paving the way for lung care teams to begin using VIDA's analysis at the point of care. The Japan market certification extends our imaging intelligence platform to millions. 

In May, we made a splash at ATS, happy to once again connect in person with our customers and partners. At the show, we introduced new biomarkers and retrospective data analysis services, as well as the expansion of the VIDA Network beyond 1,000 sites globally.

Also in May, we announced financing and new hires as we scaled up to support strong demand for VIDA lung intelligence.

In the Fall, we were excited to announce our partnership with RAYUS Radiology. This partnership empowers imaging sites for decentralized clinical trials and significantly expands the VIDA site network.

Most recently, in conjunction with the annual RSNA conference, we released VIDA Intelligence Portal 2.0. In this release, we shared that our portal is now embraced by more than 1,000 global sites!

Webinars

As we move into the new year we look forward to having more guests join us on our popular webinar series, though we are not sure how we'll top 2022!

In February, MeiLan Han, MD, MS joined us to discuss the importance of protecting our lungs and shared fascinating insights from her book Breathing Lessons: A Doctor's Guide to Lung Health. Alejandro Comellas, MD joined us in August to review findings from the current and ongoing impact of Long COVID. Then last month, Grace Parraga, PhD dove into investigating lung structure and function. We'll have our next webinar posted here soon!

VIDA in the News

We were honored to be recognized by the media throughout the year for our advancements in imaging intelligence. 

Three Steps to Improving Respiratory Clinical Trials and Advancing New Therapies - Pharmaceutical Outsourcing, May 2022

The Disruptive Impact of AI and Precision Lung Data on Respiratory Trials - Inside Precision Medicine, June 2022

How COVID is Forcing a Reckoning in Respiratory Clinical Trials - Applied Clinical Trials, July 2022

AI Biomarkers and the effects of treating lung disease - The Med-Talk Podcast, August 2022



Advantages of Precision Endpoints - Applied Clinical Trials Podcast, November 2022

How “Lung Intelligence” is Accelerating New Therapies - MedCity News, December 2022

Research Collaborations

VIDA's imaging intelligence appears in more than 200 journal publications. Over the past year, collaborators continued to utilize VIDA's biomarkers in research. Highlights include:  

ERS 2022 Late Breaking Abstract -- Congratulations to Chris Brightling, MD, Lars Haug Nordenmark, PhD, and colleagues on their pioneering study presented at ERS. Tezepelumab is the first biologic therapy shown to reduce mucus plugs in Eosinophilic Asthma. The role of mucus in eosinophilic asthma is increasingly understood to be a key element of the disease process. VIDA was proud to partner on this study for mucus plug quantification.

Mummy et al. Mucus plugs in asthma at CT associated with regional ventilation defects at 3He MRI. Radiology. 2022 Apr;303(1):184-190. doi: 10.1148/radiol.2021204616. 

"Airway mucus plugging at CT was associated with reduced ventilation in the same bronchopulmonary segment at hyperpolarized helium 3 MRI, suggesting that mucus plugging may be an important cause of ventilation defects in asthma."

Alkhanfar et al. Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. ERJ Open Res. 2022 May;8(2):00503-2021. doi: 10.1183/23120541.00503-2021  

"Patients with severe Pulmonary Hypertension (PH)-Chronic Lung Disease (CLD), regardless of aetiology, have lower small pulmonary vessel volume compared to patients with mild–moderate PH-CLD, and this is associated with a higher mortality."

Moslemi et al.

"The combination of CT lung imaging and conventional measurements leads to greater prediction accuracy of subsequent health services use than conventional measurements alone, and may provide needed prognostic information for patients suffering from COPD."

Cho, Villacreses et al.

"The percentage of lung affected by air trapping was similar across COVID-19 severity groups and persisted in eight of nine participants imaged more than 200 days after diagnosis. Air trapping correlated with measurements of lung volumes but not spirometry."

Trivedi et al. Quantitative CT characteristics of cluster phenotypes in the Severe Asthma Research Program cohorts. Radiology. 2022 Aug;304(2):450-459. doi: 10.1148/radiol.210363. 

"Quantitative CT assessments of the degree and intra-individual regional variability of lung expansion distinguished between well-established clinical phenotypes among participants with asthma from the Severe Asthma Research Program (SARP) study."

McIntosh, Kooner et al.

"Xe ventilation significantly improved in participants with uncontrolled asthma and in those with significant mucus plugging after a single dose of benralizumab."

Moslemi et al.

"COPD and asthma can be differentiated using machine learning with moderate-to-high accuracy by a subset of only seven CT features."

Tattersall et al.

"Asthmatic participants have lower paraspinous muscle density (PSMD), reflecting greater muscle fat infiltration. Baseline PSMD predicted lung function decline among females with asthma, but not males. These data support an important role of metabolic dysfunction in lung function decline." 

Tran et al.

"There was increased airway wall thickness and reduced airway counts on CT in segments where there was a distal mucus plug compared to segments without mucus plugs in asthma and COPD." 

Shahin et al.

"The volume of pulmonary small vessels is reduced in pulmonary arterial hypertension and pulmonary hypertension (PH) associated with left heart disease, with similar volume of peel vessels compared with controls. For chronic thromboembolic PH, the volume of peel vessels is reduced. In PH, small pulmonary vessel volume is associated with pulmonary function tests." 

Our VIDA Family

We have the best team here at VIDA. This deeply collaborative group of smart and kind humans work very hard, but we saved time for fun in 2022 as well. Here are a collection of favorite memories from this year.

We look forward to our continued partnership and the advancements we'll make together in 2023.

Wishing you Happy Holidays and a wonderful New Year!